![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » J&J SECURES TOPAMAX INJUNCTION
J&J SECURES TOPAMAX INJUNCTION
At the request of Ortho-McNeil, a Johnson & Johnson (J&J) subsidiary, a court has issued a preliminary injunction against Mylan's generic topiramate product.
The U.S. District Court for the District of New Jersey granted the injunction, preventing Mylan from launching a generic version of the epilepsy drug Topamax (topiramate), J&J announced Oct. 20. Mylan will not be able to market a version of this drug before a final court decision on the validity of J&J's patent. A trial date has not yet been set, and the patent is set to expire in September 2008.
Topamax is indicated for use in epilepsy patients and to treat migraines.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct